Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1002 USD | -22.92% | -46.70% | +22.94% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 4.923 | 10.26 | 7.322 | 15.37 | 7.565 | 2.567 |
Enterprise Value (EV) 1 | 11.21 | 15.55 | 12.85 | 22.62 | 13.15 | 13.29 |
P/E ratio | -12.9 x | -7.34 x | -9.84 x | -1.76 x | 85.3 x | -0.87 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.21 x | 0.47 x | 0.37 x | 0.94 x | 0.48 x | 0.14 x |
EV / Revenue | 0.48 x | 0.72 x | 0.65 x | 1.38 x | 0.83 x | 0.73 x |
EV / EBITDA | 10.1 x | -46.7 x | -1.77 x | -3.34 x | -16.1 x | -6.63 x |
EV / FCF | -8.15 x | 29.1 x | -4.87 x | -668 x | -48.9 x | -30.6 x |
FCF Yield | -12.3% | 3.43% | -20.5% | -0.15% | -2.04% | -3.27% |
Price to Book | 0.67 x | 1.44 x | 1.01 x | 12.4 x | 2.34 x | 2.38 x |
Nbr of stocks (in thousands) | 8,122 | 9,284 | 9,634 | 11,554 | 12,823 | 13,400 |
Reference price 2 | 0.6061 | 1.105 | 0.7600 | 1.330 | 0.5900 | 0.1916 |
Announcement Date | 4/2/18 | 4/1/19 | 4/13/20 | 3/25/21 | 3/31/22 | 4/17/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 23.28 | 21.71 | 19.84 | 16.38 | 15.75 | 18.12 |
EBITDA 1 | 1.105 | -0.333 | -7.254 | -6.769 | -0.816 | -2.006 |
EBIT 1 | 0.463 | -0.854 | -7.641 | -7.114 | -1.156 | -2.131 |
Operating Margin | 1.99% | -3.93% | -38.51% | -43.43% | -7.34% | -11.76% |
Earnings before Tax (EBT) 1 | -0.402 | -1.416 | -0.727 | -7.459 | 0.099 | -2.92 |
Net income 1 | -0.384 | -1.339 | -0.742 | -7.474 | 0.084 | -2.92 |
Net margin | -1.65% | -6.17% | -3.74% | -45.63% | 0.53% | -16.12% |
EPS 2 | -0.0469 | -0.1505 | -0.0773 | -0.7551 | 0.006913 | -0.2200 |
Free Cash Flow 1 | -1.374 | 0.534 | -2.638 | -0.0339 | -0.2688 | -0.434 |
FCF margin | -5.9% | 2.46% | -13.29% | -0.21% | -1.71% | -2.4% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/2/18 | 4/1/19 | 4/13/20 | 3/25/21 | 3/31/22 | 4/17/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 6.29 | 5.29 | 5.53 | 7.26 | 5.59 | 10.7 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 5.689 x | -15.89 x | -0.7626 x | -1.072 x | -6.848 x | -5.345 x |
Free Cash Flow 1 | -1.37 | 0.53 | -2.64 | -0.03 | -0.27 | -0.43 |
ROE (net income / shareholders' equity) | -5.51% | -18.4% | -10.2% | -174% | 3.72% | -134% |
ROA (Net income/ Total Assets) | 1.92% | -3.47% | -28.1% | -30.2% | -6.27% | -9.9% |
Assets 1 | -20.02 | 38.6 | 2.637 | 24.78 | -1.339 | 29.5 |
Book Value Per Share 2 | 0.9000 | 0.7700 | 0.7500 | 0.1100 | 0.2500 | 0.0800 |
Cash Flow per Share 2 | 0.0200 | 0.0600 | 0.0600 | 0.0100 | 0.0200 | 0.0100 |
Capex 1 | 0.14 | 0.08 | 0.26 | 0.17 | 0.03 | 0.05 |
Capex / Sales | 0.59% | 0.37% | 1.33% | 1.01% | 0.2% | 0.26% |
Announcement Date | 4/2/18 | 4/1/19 | 4/13/20 | 3/25/21 | 3/31/22 | 4/17/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+22.94% | 1.89M | |
-5.52% | 194B | |
+11.67% | 82.95B | |
+62.17% | 66.91B | |
+10.90% | 57.73B | |
+12.73% | 27.55B | |
+12.86% | 20.23B | |
+66.24% | 20.06B | |
+9.06% | 17.63B | |
-10.51% | 17.46B |
- Stock Market
- Equities
- BDRL Stock
- Financials Blonder Tongue Laboratories, Inc.